Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Orphazyme Shares Rocketed Higher on Wednesday

By Cory Renauer – Jun 16, 2021 at 3:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A sign there could be a buyout offer on the table sent this volatile biotech stock through the roof today.

What happened

Shares of Orphazyme AS (ORPH), a clinical-stage biopharmaceutical company, shot through the roof on Wednesday after the company disclosed a significant sale from one of its largest shareholders. Retail investors, convinced this is a sign the company was preparing for a buyout offer, pushed the volatile biotech stock 77.1% higher as of 3:23 p.m. EDT.

So what 

On Jun. 15, 2021, Orphazyme made a disclosure to investors regarding one of the company's largest investors, the Sunstone Life Ventures fund. The company didn't disclose how many shares Sunstone sold, but it was enough to lower its share of voting rights below a 5% threshold that required the disclosure. Some investors took this as a sign Sunstone was getting out of the way to make room for a potential merger. 

Physician speaking with a patient.

Image source: Getty Images.

Orphazyme doesn't have any reliable sources of revenue yet, but that could change any day now. On or before Jun. 17, 2021, the FDA is expected to issue an approval decision regarding an application for the company's lead candidate, arimoclomol. If given a green light, it will become the first treatment specifically approved for around 1,800 Americans with an ultra-rare lysosomal storage disorder called Neimann-Pick Disease Type C.

If approved, arimoclomol could end up competing with Zavesca, a drug from Johnson & Johnson (JNJ -0.71%) that is already approved to treat other lysosomal disorders. Back in 2010, the FDA refused to complete its review of Zavesca's active ingredient until it had more data that never materialized.

Now what

It's possible the Sunstone Life Science Ventures Fund is just getting out of the way to make room for a buyout, but highly unlikely. 

Arimoclomol helps little vesicles called lysosomes transport cholesterol and other important lipids through cells by boosting the production of heat shock proteins. If greenlighted, it would be the first heat shock protein booster approved by the FDA to treat anything.

The FDA generally doesn't like to unleash completely new drugs without clear evidence of a benefit. Unfortunately, the clinical trial data supporting arimoclomol application isn't as strong as Orphazyme investors would like it to be.  

Arimoclomol narrowly missed meeting the primary endpoint in its pivotal trial with NPC patients. More recently it's also missed primary endpoints in trials with inclusion body myositis patients and amyotrophic lateral sclerosis patients.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Orphazyme A/S Stock Quote
Orphazyme A/S
Johnson & Johnson Stock Quote
Johnson & Johnson
$163.36 (-0.71%) $-1.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.